VYN201

About Vyne Therapeutics

VYNE Therapeutics is a publicly-traded biotech company (NASDAQ: VYNE) that questions traditional assumptions to develop better solutions for challenging therapeutic areas, primarily in dermatology and inflammation. Its core technology is the InhiBET™ platform of bromodomain and extra-terminal (BET) inhibitors, with lead candidates VYN201 and VYN202. In a transformative move, VYNE has entered into a definitive merger agreement with Yarrow Bioscience, which will bring in a late-stage clinical asset (YB-101) and approximately $200 million in pre-closing financing, aiming to create a combined company with a diversified pipeline and extended cash runway into 2028.

Therapeutic Areas